PharmaCyte Biotech Announces Genetic Stability Of Cytochrome P450 Gene and Site of Integration
PharmaCyte Biotech, Inc., a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced the results of an additional, more finely detailed, analysis of the integration site of the cytochrome P450 2B1 gene from the augmented HEK293 cell clone that is used in PharmaCyte’s pancreatic cancer product candidate known as CypCaps.
Latest Aithority Insights: Kid-systeme Partners With Neutral Digital To Step Into The Metaverse
Previous studies that PharmaCyte conducted showed that the cytochrome P450 2B1 gene in the augmented HEK293 cell clone was located on human chromosome 9. As PharmaCyte announced on December 8, 2021, the flanking sequence around the site of integration was sequenced in its entirety. In this new study, PharmaCyte has been able to confirm the previously elucidated structure of the integrated transgene sequence using more data points.
Browse The Complete News About Aithority: TCS Positioned as a Leader in Gartner Magic Quadrant for Data and Analytics Service Providers
These studies also set the stage for a next step analysis to determine the genetic stability of the cytochrome P450 2B1 gene at the DNA level after multiple rounds of cell growth. This new study was completed by comparing the original Research Cell Bank cells with cells from the Master Cell Bank, and the analysis confirmed that the cytochrome P450 2B1 and the surrounding sequence has remained stable with no changes detected at the DNA level.
PharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box.” This technology is being used as a platform upon which therapies for several types of cancer and diabetes are being developed.
Read More About Aithority News : Accenture Helping Navitaire Accelerate Its Journey to the Cloud
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.